Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
Gilead Sciences has formed a broad alliance with Sangamo Therapeutics this morning, continuing an aggressive push into cellular immunotherapy that began late last year.
Kallyope is unusual among biotech startups. Exclusively borne from the work of three Columbia University professors, the company started up in Manhattan, now has more than 40 employees, has gotten... Read more »
The immuno-oncology combination frenzy continues. Merck this morning agreed to pay $394 million for Viralytics, an Australian developer of oncolytic viruses, which could help boost the power of the pharma... Read more »
Wave Life Sciences this morning inked a wide-ranging alliance with Japanese pharma Takeda to develop RNA-based drugs for a variety of neurological diseases.
At a time when uncertainty again swirls around the development of Alzheimer’s disease drugs, research continues in new ways. Through an alliance this morning, Voyager Therapeutics will team with AbbVie to... Read more »
Tetraphase Pharmaceuticals’ ups and downs have continued, as new data have clouded the future of the Watertown, MA, company’s experimental antibiotic, eravacycline, once again.
The opioid crisis. Right to Try legislation. The first human trials of CRISPR-Cas9 gene editing technology. These are just a few of the many topics at the feet of the FDA... Read more »
With multiple products on the market and many more coming, it’s easy to think that cancer immunotherapy has arrived. In reality, however, we’ve only just begun to figure out how to... Read more »
The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018.
A big domino... Read more »
Verastem has filed for FDA approval of duvelisib, a blood cancer drug the Needham, MA, company took a shot on in a 2016 bargain deal with Infinity Pharmaceuticals.
Verastem will seek... Read more »
Sema4, the company that computational geneticist Eric Schadt spun out of the Icahn School of Medicine at Mount Sinai last year, is making a new bet this morning. The New York... Read more »
The push to treat migraines with a new class of medicines took another turn on Tuesday when Allergan presented clinical data for an experimental pill meant to help fend off the... Read more »
Moderna Therapeutics, the secretive messenger RNA drugmaker known in part for its preponderance of massive funding raises, has struck once again.
The Cambridge, MA, company has closed yet another huge round,... Read more »
Partner Therapeutics, a Boston startup launched last week by a pair of former Merrimack Pharmaceuticals and Seragon Pharmaceuticals executives, has raised $60 million and acquired an immune system-boosting drug from Sanofi... Read more »
In the latest in a recent spate of biopharma buyouts, Seattle Genetics has struck a deal to acquire Cascadian Therapeutics, gambling on an experimental breast cancer drug in late-stage testing.... Read more »
[Updated, 1/31/18, see below] Gene therapy pioneer James Wilson and University of Pennsylvania colleagues sounded an alarm Tuesday morning about the use of gene therapy to treat severe diseases... Read more »
Another drug that may help alleviate some of the debilitating symptoms of Parkinson’s disease is on its way to an FDA review, setting up a possible commercial battle between two drug... Read more »
[Updated, 1/26/18, see below] Solid Biosciences was expected to ride gene therapy’s wave of recent momentum to an IPO this week. But new revelations have clouded the offering, as... Read more »
If you had $100 million to create an epicenter for New York biotech, what would you do with it?
The New York City Economic Development Corp., a quasi-governmental agency supporting job... Read more »
Two top drugmakers, Sanofi and Celgene, agreed on Monday morning to shell out more than $20 billion combined, cinching deals for hemophilia drug maker Bioverativ and cell therapy developer Juno Therapeutics.... Read more »
April 26, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.